Welcome to our dedicated page for Compugen SEC filings (Ticker: CGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Compugen Ltd (CGEN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including its ongoing series of Form 6-K current reports. As a foreign private issuer, Compugen uses these filings to furnish investors with financial results, clinical and corporate updates, and details of material agreements.
Recent Form 6-K filings include quarterly financial statements and management’s discussion and analysis, which outline revenues from collaboration and license agreements, research and development expenses, general and administrative costs, and information on cash, cash equivalents, short-term deposits, and investments in marketable securities. These filings help investors understand how Compugen funds its clinical-stage cancer immunotherapy programs and how long its reported cash runway is expected to support operations.
Compugen’s 6-K reports also furnish press releases on key corporate events. Examples include announcements of second and third quarter results, initiation of the MAIA-ovarian platform trial of COM701, pooled analyses of COM701 Phase 1 trials in platinum-resistant ovarian cancer, and presentations of GS-0321 (COM503) trial designs. Another 6-K describes an amendment to the company’s license agreement with a member of the AstraZeneca Group, under which Compugen sold a portion of its royalty interest in rilvegostomig in exchange for an upfront payment and an increased milestone payment tied to Biologics License Application acceptance.
Through Stock Titan, users can review these filings alongside AI-powered summaries that explain the main points of each document, such as changes to collaboration economics, updates on clinical development, and the results of shareholder meetings. The filings page is a central resource for analyzing how Compugen reports its progress, manages its partnerships with AstraZeneca and Gilead, and discloses financial and operational information to the market.
Compugen Ltd SVP of Business Development Zurit Levine exercised options and sold shares in a pre-planned transaction. On April 24, 2026, she exercised 2,000 share options at $1.15 per share and sold 2,000 ordinary shares at $3.20 per share in an open-market sale pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025. Following these transactions, she directly held 29,375 ordinary shares.
Compugen Ltd President and CEO Ophir Eran reported an exercise-and-sale transaction in the company’s Ordinary Shares. On April 24, 2026, he exercised options to acquire 5,000 shares at an exercise price of $0.8292 per share and sold 5,000 shares in open-market trades at a weighted average price of $3.2001 per share. Following these transactions, he directly holds 11,375 Ordinary Shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 26, 2025.
Ophir Eran submitted a Form 144 notice indicating proposed sales of 5,000 ordinary shares under an Employee Stock Option Plan with cash upon exercise as the consideration method. The filing also lists recent sales of 5,625 shares on 04/01/2026 and 5,000 shares on 04/14/2026.
CGEN affiliate files a Form 144 reporting proposed and recent share sales. The filing lists 4,000 Ordinary shares to be sold under an Employee Stock Options plan with cash upon exercise. The filing also reports multiple sales by Levine Zurit totaling reported disposals across March–April 2026, each showing share counts and gross proceeds.
Compugen Ltd President and CEO Ophir Eran exercised options to acquire 5,000 ordinary shares at an exercise price of $0.8292 per share, then sold 5,000 shares in an open-market transaction at a weighted average price of $2.9042.
The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 26, 2025. Following these transactions, Eran directly owns 11,375 ordinary shares. The exercised option was from a grant that vested over time through quarterly installments.
Compugen Ltd SVP of Business Development Zurit Levine exercised stock options and sold a small portion of shares. On April 14, 2026, she exercised options for 2,000 Ordinary Shares at $1.15 per share and sold 2,000 Ordinary Shares at $2.80 per share in an open-market transaction.
These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025. Following the sale, she directly holds 29,375 Ordinary Shares, reflecting a relatively modest reduction in her equity position.
Compugen Ltd SVP of Business Development Zurit Levine exercised stock options and sold shares in a planned transaction. On April 10, 2026, she exercised options for 3,125 Ordinary Shares at exercise prices of $0.8292 and $1.15, then sold 3,125 Ordinary Shares at a weighted average price of $2.564 pursuant to a Rule 10b5-1 trading plan. Following these transactions, she directly holds 29,375 Ordinary Shares.
Ophir Eran submitted a Form 144 notice to sell 5,000 Ordinary shares of the issuer tied to an Employee Stock Option Plan, with the filing date shown as 04/14/2026. The record shows prior sales of 5,626 Ordinary shares on 04/01/2026 with an amount listed as 12412.68.
CGEN submitted a Rule 144 notice reporting an intended sale of 2,000 ordinary shares under an Employee Stock Options plan, with the sale dated 04/14/2026 and listed as Cash - Upon Exercise. The filing also lists a prior sale of 26,375 shares on 03/26/2026 generating $58,657.50.
Compugen Ltd. senior vice president Zurit Levine exercised share options and sold shares in a planned transaction. On April 10, 2026, she exercised options for a total of 3,125 Ordinary Shares at strike prices of $0.8292 and $1.15 per share, then sold 3,125 Ordinary Shares at a weighted average price of $2.564 per share under a Rule 10b5-1 trading plan. Following these transactions, she holds 29,375 Ordinary Shares directly and retains share option positions totaling 5,625 and 56,000 options, respectively.